Introduction Biosimilar monoclonal antibodies (mAbs) are biologic drugs designed to be highly similar to already approved reference monoclonal ...

Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, ...

While current top products could see new branded and biosimilar threats over the next several years, the combined Roche-Chugai pipeline is robust and promising. Chugai was founded in 1925 and ...

Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) today published its audited consolidated financial statements for the 2024 financial year and provided an outlook for fiscal year 2025 ...

SHANGHAI, China & JERSEY CITY, NJ, USA I March 28, 2025 I Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the ...

We have the strongest in-house developed product pipeline in the biosimilar industry based on official available data. Ten products are in advanced development and additionally 18 molecules have ...

At the same time, our strong in-house R&D capabilities have put Alvotech in a leading position among pure play biosimilar companies in terms of the market value of our product pipeline.

I Gedeon Richter Plc. announces today that the European Medicines Agency has accepted Richter’s marketing authorization application (MAA) for ...

(Gedeon Richter), and the associated cash capital increase at the beginning of 2024, allowed Formycon to raise €82.84 million for the further development of its existing biosimilar pipeline. In return ...

Amgen expects key drugs like Repatha, Evenity, Tezspire and oncology and rare disease drugs, as well as biosimilars to drive top-line growth in 2025. Amgen also has some key pipeline assets in ...

Henlius has pro-actively built a diversified and high-quality product pipeline covering about 50 ... (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab, trade name: HERCESSI ...